Pain Management

Introduction to Pain Management

The National Comprehensive Cancer Network recommends the use of multimodal analgesia, which includes a combination of medications, as part of cancer pain management 1, 2

Diclofenac is recommended for inflammatory pain conditions, particularly for osteoarthritis, acute musculoskeletal pain, and as a topical agent for localized pain, using the lowest effective dose for the shortest duration possible to minimize adverse effects, as recommended by the MMWR Recommendations and Reports, the American College of Physicians, and the National Comprehensive Cancer Network 3, 4, 1
The American College of Physicians suggests considering diclofenac as part of combination therapy with acetaminophen and/or triptans for migraine headache, with a moderate strength of evidence 4
Diclofenac is effective for short-term management of acute musculoskeletal pain, with a recommendation from general medical knowledge, although the specific guideline is not provided 3

Topical application of diclofenac is preferred for localized pain, especially in osteoarthritis of superficial joints, with diclofenac gel applied 3 times daily and diclofenac patch (180 mg) applied once or twice daily, as recommended by the Journal of the National Comprehensive Cancer Network and the National Comprehensive Cancer Network 1
Oral administration of diclofenac should use the lowest effective dose (typically 50-150 mg/day divided) and consider gastric protection for long-term use, as a general medical recommendation and supported by the European Society for Medical Oncology and the American College of Rheumatology 3, 5
The American College of Rheumatology recommends a maximum daily dose of 150-200 mg depending on the condition, with a moderate strength of evidence 5
For chronic non-bacterial osteitis (CNO), the starting dose is 150 mg/day in divided doses, with a maintenance dose of 75-100 mg/day in divided doses, according to the European League Against Rheumatism 6
For acute pain management, typically 150 mg/day of diclofenac is used, as suggested by the European Society for Medical Oncology 5
For mild pain (NRS 1-4), consider non-opioid alternatives first, and if NSAID is indicated, start with diclofenac 50 mg twice daily, as recommended by the British Society of Sports Medicine and the European Society for Medical Oncology 5, 7

Patients with cardiovascular disease are at increased risk of cardiovascular events, particularly with diclofenac, as noted by MMWR Recommendations and Reports and the European Society of Cardiology 3, 5
Combination therapy with other analgesics (e.g., acetaminophen) can improve efficacy while minimizing NSAID dose for chronic pain conditions, according to MMWR Recommendations and Reports and supported by the European Society for Medical Oncology 3, 5
Diclofenac may delay natural healing processes since inflammation is a necessary component of tissue recovery, and significant drug interactions should be considered, as noted by the British Society of Sports Medicine and the Cochrane Review 7, 8
For elderly or debilitated patients, no specific dosage adjustment is required, but use caution due to increased risk of adverse effects, as advised by the American Geriatrics Society 9

Treatment response should be evaluated after 2-4 weeks, and monitoring for gastrointestinal, renal, and cardiovascular adverse effects is necessary, as recommended by the European League Against Rheumatism, the British Society of Sports Medicine, and the European Society of Cardiology 6, 7, 5
If more than four breakthrough doses of pain medication are needed in 24 hours, consider increasing the diclofenac dose, as recommended by the American Geriatrics Society and the European Society for Medical Oncology 9, 5
Regular assessment for gastrointestinal, renal, and cardiovascular adverse effects is essential for patients on long-term therapy, as recommended by the European Society of Cardiology and the British Society of Sports Medicine 5, 7

Diclofenac has been shown to have a similar efficacy to other NSAIDs for pain management, but the strength of evidence is moderate, according to the Cochrane Review 8
NSAIDs may delay natural healing processes, as inflammation suppressed is a necessary component of tissue recovery, as noted by the British Society of Sports Medicine and the Cochrane Review 7, 8